Login / Signup

Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis.

Marie MaerevoetRené-Olivier CasasnovasGuillaume CartronFranck MorschhauserCatherine ThieblemontKamal BouabdallahPierre FeugierVanessa SzablewskiStephanie BeckerHerve Tilly
Published in: Cancers (2024)
Among the patients with R/R B-cell lymphoma, selinexor at a weekly dose of 40 mg with R-GDP is feasible for outpatients, with a generally acceptable safety profile.
Keyphrases
  • diffuse large b cell lymphoma
  • hodgkin lymphoma
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • multiple myeloma